Establishment Labs(ESTA) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Q4 2025 revenue was $64.6 million, a 45.2% increase compared to Q4 2024, with total revenue for 2025 reaching $211.1 million, up 27.2% from 2024 [3][4] - Q4 net loss from operations was $3.9 million, down 79% from Q4 2024, while adjusted EBITDA was positive at $5.5 million, compared to a loss of $13.1 million in Q4 2024 [4][24] - The ending cash balance for 2025 was $75.6 million, indicating no need for additional capital [4] Business Line Data and Key Metrics Changes - U.S. Motiva revenue in 2025 was $45.6 million, contributing significantly to overall growth [3] - Gross margin for Q4 was 70.5%, a 200 basis point increase from the previous year, with overall gross profit margin increasing 330 basis points in 2025 [22][23] Market Data and Key Metrics Changes - Sales in Europe, the Middle East, and Africa accounted for 41% of global total sales in Q4, with strong growth in direct markets [22] - Latin America represented 18% of sales, with stable results in Brazil and strong growth in Argentina [22][23] - Asia Pacific accounted for 14.1% of sales, with improved performance in China [22][19] Company Strategy and Development Direction - The company aims to transform the breast aesthetics industry through innovation, with a focus on minimally invasive procedures like Preservé [6][12] - Plans to expand the U.S. sales force by adding up to 15 more representatives to drive market penetration [11][26] - The introduction of Motiva implants for breast reconstruction is expected to double the total addressable market in the U.S. [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity in 2026 and expects significant growth in 2027 [4][30] - The U.S. market remains healthy, with strong demand for breast augmentation procedures and a positive outlook for the minimally invasive portfolio [52][60] - The company is focused on maintaining operational momentum while preparing for future growth phases [20][21] Other Important Information - The company is actively working on FDA approvals for new products, including smaller sizes and reconstruction options, which are expected to enhance market share [18][69] - Establishment Labs is also considering refinancing options for its credit facility as it approaches the end of its term [26] Q&A Session Summary Question: Thoughts on the minimally invasive portfolio and market growth - Management noted strong early experiences with Preservé and Mia, indicating a positive trajectory for market growth and patient interest [33][35] Question: U.S. revenue and sales representative expansion - The company is focused on hiring experienced sales representatives to enhance market penetration and drive growth [36][38] Question: Plans for reconstruction market entry - Management highlighted the significant opportunity in the reconstruction market, with plans to expand the sales force and leverage existing relationships [40][41] Question: International growth and underlying demand - Management confirmed that international markets are showing healthy demand, with no significant one-off factors affecting growth [43][44] Question: Global market conditions and augmentation procedures - The overall market for breast augmentation procedures is healthy, with increasing interest and demand across various regions [51][54] Question: Contribution of pipeline products to revenue guidance - Reconstruction is expected to be more of a 2027 story, while Preservé is anticipated to drive significant revenue growth in 2026 [68][70]